Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a monthly compilation of research articles funded by AHRQ or authored by AHRQ researchers and recently published in journals or newsletters.
Results
1 to 2 of 2 Research Studies DisplayedChabra S, Hofstetter AM
Timely hepatitis B birth dose receipt for newborns: within 24 hours.
In this paper, the authors discuss the importance of timely administration of the hepatitis B birth dose to achieve the national goal of zero perinatal hepatitis B transmission in the near future. They state that the necessity of capturing vaccination opportunities in diverse health care settings is clearly evident during the coronavirus pandemic.
AHRQ-funded; HS025470.
Citation: Chabra S, Hofstetter AM .
Timely hepatitis B birth dose receipt for newborns: within 24 hours.
Hosp Pediatr 2020 Dec;10(12):e18-e20. doi: 10.1542/hpeds.2020-001255..
Keywords: Newborns/Infants, Hepatitis, Vaccination
Simons BC, Spradling PR, Bruden DJ
A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen.
The purpose of this paper is to determine long-lasting protection resulting from hepatitis B vaccine, despite loss of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs). All participants tested positive for tumor necrosis factor α, interleukin 10, or interleukin 6 production by HBV surface antigen-specific T cells. No participant had evidence of breakthrough HBV infection. The authors concluded that protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 32 years.
AHRQ-funded; HS000046.
Citation: Simons BC, Spradling PR, Bruden DJ .
A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen.
J Infect Dis 2016 Jul 15;214(2):273-80. doi: 10.1093/infdis/jiw142.
.
.
Keywords: Hepatitis, Prevention, Vaccination